Dr. Reddy's Laboratories Limited (RDY) Income Statement

The 8.6% year-over-year growth in the latest quarter masks a sequential decline from $88.1B in 2026Q2 to $81.2B in 2027Q1, indicating a loss of steam. This deceleration appears driven by base business price erosion in the US and potential launch timing gaps, as the company's complex generic pipeline may not be replenishing fast enough to offset declines. Investors should monitor whether this is a temporary trough or the start of a sustained downturn.

The 14-point gross margin erosion over eight quarters suggests a structural deterioration, not just quarterly noise. This likely stems from increased competition in key generic molecules and a higher proportion of lower-margin API sales. The company's vertical integration may be insufficient to shield margins as US price erosion persists, warranting close watch on whether new complex launches can restore profitability.

The dramatic fall in operating income—despite only a modest revenue decline—indicates that fixed costs, particularly R&D and SG&A, are not scaling down with revenue. SG&A remained elevated at $29.0B in 2027Q1, nearly flat versus prior quarters, while gross profit shrank, crushing operating leverage. This suggests the cost base is too rigid for the current revenue environment, and management may need to reassess expense discipline.

This inflection point appears driven by a combination of strong complex generic launches and favorable US pricing, which boosted margins to unsustainable levels. The subsequent decline through 2027Q1 indicates that the competitive landscape and pricing dynamics have shifted, eroding the advantages that drove peak performance. The lasting impact is a higher cost base and a pipeline that may not deliver similar margin contributions, suggesting the company's earnings power has structurally declined.